PALO ALTO, Calif., May 16, 2018 /PRNewswire/ -- Varian (NYSE: VAR) announced two patients with brain cancer were the firstpatients in Korea to be treated using the company's HyperArc™ High Definition Radiotherapy (HDRT), a new type of radiosurgery treatment, at the Ajou University Hospital. HyperArc is designed to automate and simplify sophisticated treatments
"We have been utilizing Varian's cancer treatment technology for over 20 years with great success," said Dr. Young-Taek Oh, chief oncologist, Ajou University Hospital. "HyperArc treatments are a big step forward for both clinicians and patients, and we look forward to quickly expanding the use of these treatments at our clinic."
"We are excited that HyperArc treatments have begun in Korea," said Kenneth Tan, managing director South East Asia & Korea of Varian's Oncology Systems business. "By partnering with leading institutions like Ajou University Hospital to deliver advanced cancer treatments to more patients, we are taking another important step in achieving our vision of a world without fear of cancer."
HyperArc capitalizes on the unique capabilities of Varian's TrueBeam™ and EDGE™ treatment systems. HyperArc treatments allow clinicians the ability to deliver more compact radiation doses that closely conform to the size, shape, and location of tumors while sparing more surrounding healthy tissue. These advanced treatments can be delivered in a conventional treatment time slot. The treatment planning for HyperArc is supported by Varian's Eclipse™ treatment planning software.
For more information on HyperArc, visit www.varian.com/hyperarc
About Varian Varian is a leader in developing and delivering cancer care solutions, and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,500 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
Press ContactMark PlungyDirector, Public Relations+1 (650) 424-5630 email@example.com
Investor Relations ContactJ. Michael BruffSenior Vice President, Investor Relations+1 (650) 424-5163 firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/first-cancer-patients-in-korea-treated-with-varian-hyperarc-high-definition-radiotherapy-300648501.html
Subscribe to our Free Newsletters!
Osteolysis refers to breaking down of bone tissue. Bone loss occurs due to resorption of bone by ...
Patisiran injection, recently approved by FDA to treat polyneuropathy, a disease that causes ...
Dysgraphia or disorder of written expression is a childhood learning disorder marked by poor ...View All